This clinical trial is focused on studying a condition known as refractory epilepsy, which is a type of epilepsy that does not respond well to standard treatments. The study also includes a specific form of epilepsy called Rasmussen Encephalitis, which is a rare, chronic inflammatory neurological disease. The treatment being tested in this trial is called AloCelyvir, which involves the use of special cells known as allogenic bone marrow-derived mesenchymal stem cells. These cells are modified in a laboratory setting to potentially help manage the condition.
The purpose of this study is to evaluate the safety and how well patients respond to this treatment. Participants in the trial will receive repeated doses of these stem cells through a method called intra-arterial infusion, which means the cells are delivered directly into the arteries. The study is designed for children and adolescents who have not had success with other epilepsy treatments. The trial will monitor participants over a period to observe any changes in their condition and to ensure the treatment is safe.
Throughout the study, researchers will be looking for any side effects that might occur from the treatment, as well as any improvements in the participants’ epilepsy symptoms. The trial aims to provide new insights into managing refractory epilepsy and Rasmussen Encephalitis, potentially offering new hope for those affected by these challenging conditions.
Spain 
